Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations
Abstract KRAS, a frequently mutated oncogene, has been challenging to target therapeutically. Although covalent inhibitors like sotorasib against KRASG12C have been developed, their efficacy is often limited by acquired resistance. Targeted protein degradation offers a potential solution but has lar...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Portfolio
2026-03-01
|
| Serie: | Nature Communications |
| Accesso online: | https://doi.org/10.1038/s41467-026-71093-9 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|